The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index.
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
Abstract
Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a validated algorithm ("control", 96 patients) or CYP2C9 genotype-adjusted algorithms ("study", 95 patients). The first therapeutic international normalized ratio and stable anticoagulation were reached 2.73 and 18.1 days earlier in the study group, respectively (P<0.001). The faster rate of initial anticoagulation was driven by a 28% higher daily dose in the study group (P<0.001). Study group patients spent more time within the therapeutic range (80.4 vs 63.4%, respectively, P<0.001) and experienced less minor bleeding (3.2 vs 12.5%, P<0.02, respectively). In conclusion, CYP2C9 genotype-guided warfarin therapy is more efficient and safer than the "average-dose" protocol. Future research should focus on construction of algorithms that incorporate other polymorphisms (VKORC1), host factors, and environmental influences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“[79-82] In addition, the frequency of HLA-B*1502 is higher in South Asians, including Taiwanese, Hong Kong Chinese, Thai, and Indians (8-11%), than in North Asians, such as Beijing Chinese, Japanese, and Koreans (1-2%).”
BackgroundShimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Cited by
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
CYP4F2 genetic variant alters required warfarin dose
Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122010 · Cited by 521
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Sistonen, J., Fuselli, S., Palo, J. U., Chauhan, N., Padh, H., & Sajantila, A. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831ebb30 · Cited by 200
Metadata
- Authors
- Caraco, Y., Blotnick, S., & Muszkat, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-09-12
- Volume
- 83
- Issue
- 3
- Pages
- 460-470
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2032289591
- Cited by
- 360
- References
- 279
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study. https://app.cochat.ai/papers/10.1038/sj.clpt.6100316
- The paper
- Caraco, Y., Blotnick, S., & Muszkat, M. (2008). CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/sj.clpt.6100316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
